← All trials
NCT04222647
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2020
- Primary completion
- Mar 31, 2020
- Completion date
- Mar 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 43
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dr. August Wolff GmbH & Co. KG ArzneimittelLead sponsor
- pontifical catholic universityOverall official - principal investigator
- Dr. August Wolff GmbH & Co. KG ArzneimittelStudy director
- proDERM GmbHCollaborator
- Bremer Pharmacovigilance Service GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.